May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Patient Impact of Allergic Conjunctivitis as Measured by the Eye Allergy Patient Impact Questionnaire (EAPIQ)
Author Affiliations & Notes
  • P.M. Buchholz
    Health Econ, Allergan, Ettlingen, Germany
  • J. Walt
    Health Outcomes, Allergan, Irvine, CA, United States
  • D. Lorenz
    Lake Mead Hosp, Henderson, NV, United States
  • C. Burk
    Health Outcomes, CTBurk, Inc., Laguna Bch, CA, United States
  • J. Lee
    Health Outcomes, CTBurk, Inc., Laguna Bch, CA, United States
  • Footnotes
    Commercial Relationships  P.M. Buchholz, Allergan, Inc. E; J. Walt, Allergan, Inc. E; D. Lorenz, Allergan, Inc. R; C. Burk, Allergan, Inc. C; J. Lee, Allergan E.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 3735. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.M. Buchholz, J. Walt, D. Lorenz, C. Burk, J. Lee; Patient Impact of Allergic Conjunctivitis as Measured by the Eye Allergy Patient Impact Questionnaire (EAPIQ) . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3735.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: This study assessed patients with eye allergy symptoms using the Eye Allergy Patient Impact Questionnaire (EAPIQ©). Validity of results from the EAPIQ© was evaluated using the MiniRhinoconjunctivitis Quality of Life Questionnaire(MiniRQLQ©), a previously validated instrument as a comparative measure. Methods: The EAPIQ© is a questionnaire designed to evaluate eye allergy symptoms. It consists of 36 items that are intended to assess the occurrence of these symptoms, actions taken for these symptoms, effect of these symptoms on everyday activities and emotions, and satisfaction with treatment for these symptoms. The EAPIQ was administered to allergic conjunctivitis patients at 6 different ophthalmology clinics. The EAPIQ© and MiniRQLQ© were administered at the same time to a subset of patients. Correlations of the two instruments were tested using the Pearson's correlation coefficient (r). Results: The 132 patients who completed the EAPIQ ranged in age from 16 to 88 years (mean=47, sd=16.7), 72% were female, 93% identified themselves as white, over 70% spent the majority of waking hours indoors, and nearly 40% had a professional occupation. Itchy/burning (18%) and dry eye (14%) symptoms were the most frequently reported as occurring all of the time. Peak season to experience eye allergy symptoms were April, May, and June (69%-79%). While a quarter of patients were able to perform daily tasks regardless of eye allergy symptoms, 17% were unable to perform tasks any day when symptoms were present. Patients were extremely troubled by going outdoors and by feeling tired/fatigued. In general, males were more often troubled by "emotions" due to eye allergy symptoms than females. Over 70% of patients reported having some satisfaction with their current eye medication for their eye allergy symptoms, with only 2% reporting dissatisfaction. Validity of the EAPIQ© was assessed using a subset of the population (n=49) who also completed the MiniRQLQ©. The most frequently correlated symptoms from the EAPIQ© were itchy, sore, and watery eyes which correlated with the "other symptoms" domain or functional status from the MiniRQLQ©(r=0.70, p< 0.05). Conclusions:The EAPIQ© demonstrates that patients' eye allergy symptoms affect many aspects of their daily activities. In addition to affecting functionality, these symptoms also affect patients' emotional state. Symptoms and functional status assessed in the EAPIQ© were highly correlated to symptoms assessed in the MiniRQLQ©.

Keywords: clinical (human) or epidemiologic studies: hea • clinical (human) or epidemiologic studies: nat • clinical (human) or epidemiologic studies: pre 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.